Peter Brett, MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma (NCT07733466) | Peter Brett, MD | 2026-08-15 |
Track Peter Brett, MD automatically
Every clearance here is in the API, with alerts when new ones post.